Podcast appearances and mentions of David Fischer

The Joe Piscopo Show 6-23-26 Joe Piscopo is broadcasting live from the offices of Times Square Alliance overlooking Times Square in celebration of America's 250th Anniversary. 27:49- Dr. Carlos Campo, President and CEO of Museum of the Bible Topic: Museum of the Bible 40:40- Jeff Coltin, Editor-in-Chief of City & State New York Topic: Primary Day in New York 56:21- John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: Primaries today; Three non-citizens admit to knowingly voting in federal elections despite ineligibility; Vandalism of reflecting pool; Other news of the day 1:05:27- Tom Harris, President of Times Square Alliance Topic: Broadcasting from Times Square Alliance; Upcoming events in Times Square 1:14:01- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: Iran peace talks in Switzerland 1:28:49- David Fischer, CEO of Landmark Capital Topic: Why now you should roll over a portion of your 401(k) and/or IRA into an IRA with physical gold and silver- PART 4 1:40:05- Arthur Aidala, former Brooklyn Prosecutor, star criminal defense attorney, and host of "The Arthur Aidala Power Hour" weeknights at 6 p.m. on AM 970 The Answer Topic: Broadcast from Times Square tonight 1:51:02- Mike Connors, Attorney at Law at Connors & Sullivan and host of "Ask the Lawyer," airing Saturdays at 6 p.m. and Sundays at 11 a.m. on AM 970 The Answer Topic: Broadcasting from Times Square; America's 250th Anniversary 2:06:03- Arthur Lih, Inventor & CEO of LifeVac and the author of "Sorry, Can't is a Lie" Topic: America's 250th; Portions of the proceeds of Patriots, Pasta, & Piscopo going to Equal First Aid 2:19:28- Chef Glenn Rolnick, Culinary Director of Carmine's Topic: What's on the menu for Patriots, Pasta, & Piscopo tomorrow nightSee omnystudio.com/listener for privacy information.

46:41- John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: Primaries today; Trump at the G7 summit; U.S.-Iran deal 56:15- Kyle Bailey, Aviation analyst, pilot, former FAA Safety Team representative, and the author of "Witness: JFK Jr.'s Fatal Flight" Topic: Eight killed in Air Force B-52 crash; 12 killed in skydiving plane crash in Missouri 1:06:07- Robert Greenway, Director of the Center for National Defense at The Heritage Foundation, Former Deputy Assistant to the President and Senior Director for the Middle East and North Africa in the Trump administration, and principal architect of the Abraham Accords Topic: U.S.-Iran deal 1:20:19- David Fischer, CEO of Landmark Capital Topic: “Why NOW you should roll over a portion of your 401(k) and/or IRA into a physical gold and silver IRA- PART 3 1:31:10- Chris Swecker, attorney who served as assistant director of the FBI for the Criminal Investigative Division from 2004 to 2006 Topic: Gavin Newsom says DOJ is investigating him and his wife 1:41:35- Thomas Homan, Border Czar for the Trump administration Topic: ICE agent hit by car in Manahawkin 2:03:39- Assemblyman Robert Auth, New Jersey Assemblyman representing the 39th district (Bergen & Passaic) Topic: Delaney Hall and other New Jersey newsSee omnystudio.com/listener for privacy information.

Join Stu Epperson as he interviews David Fischer of LandmarkGold.com. David gives the audience an insight into his journey to Christ!

John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice networkTopic: Primaries today; Other news of the day Pastor Corey Brooks, founder and Senior Pastor of New Beginnings Church of Chicago and founder and CEO of Project H.O.O.D. Communities Development CorporationTopic: 1 killed, 3 others injured in Chicago shooting; 22 shot, 2 fatally over the weekend in Chicago K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'”Topic: Netanyahu confirms ceasefire David Fischer, CEO of Landmark CapitalTopic: Why now you should roll over a portion of your 401(k) and/or IRA into a physical gold and silver IRA- PART 2 Commissioner Ray Kelly, the longest-serving Commissioner of the NYPD in history who was in charge of the Secret Service during his tenure as Deputy Treasury Secretary under President ClintonTopic: Policing Penn Station, World Cup, and America's 250th Hans von Spakovsky, Senior Legal Fellow in the new Edwin Meese III Institute for the Rule of Law at Advancing American FreedomTopic: Tim Walz and Minnesota AG face DOJ criminal referral; Other legal news of the daySee omnystudio.com/listener for privacy information.

The Joe Piscopo Show 6-2-26 24:15- Matt Rooney, Founder and Editor-in-Chief of SaveJersey.com Topic: Primary Day in New Jersey; Delaney Hall 34:55- Gen. Jack Keane, a retired 4-star general, the chairman of the Institute for the Study of War and Fox News Senior Strategic Analyst Topic: Latest in Iran talks 48:33- Hogan Gidley, Former National Press Secretary for the Trump campaign and former White House Deputy Press Secretary Topic: Primary Day; Latest from the Trump White House 57:00- Hans von Spakovsky, Senior Legal Fellow in the new Edwin Meese III Institute for the Rule of Law at Advancing American Freedom Topic: New Charlie Kirk assassination evidence 1:08:36- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: Latest in the Iran negotiations 1:22:28- David Fischer, CEO of Landmark Capital Topic: Why now you should roll over a portion of your 401(k) and/or IRA into a physical gold and silver IRA- How it reduces your financial risk 1:33:29- David Wildstein, Founder and Editor-in-Chief of New Jersey Globe Topic: Primaries in New Jersey 1:42:38- Larry Elder, host of "The Larry Elder Show" on the Salem Radio Network, author of "As Goes California: My Mission to Rescue the Golden State and Save the Nation" and the host of the "We’ve Got A Country to Save" podcast Topic: Primary Day in California 2:03:22- Tony Danza, actor and entertainer best remembered for his roles on "Taxi" and "Who's the Boss?" Topic: Upcoming show in Pottstown, PA on Saturday; His storied careerSee omnystudio.com/listener for privacy information.

24:29- Jeff James, Retired Assistant Special Agent in Charge with the U.S. Secret Service Topic: Gunman killed after opening fire on Secret Service checkpoint outside the White House 34:55- Col. Jack Jacobs, a retired colonel in the United States Army and a Medal of Honor recipient for his actions during the Vietnam War Topic: U.S. self-defense strikes in Iran 49:07- Kate Lisa, New York Politics Reporter at City & State NY Topics: President Trump in Rockland County 1:08:59- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: Latest in the negotiations with Iran 1:23:05- David Fischer, CEO of Landmark Capital Topic: Inflation; Gold in Fort Knox; David's limited-time offer 1:42:46- Gregg Jarrett, Legal and political analyst for Fox News Channel and the author of "The Trial Of The Century" Topic: Cracking down on fraud; Other legal news of the day 1:55:18- Raymond Arroyo, managing editor & host of "The World Over" on EWTN, host of the "Arroyo Grande" podcast, and a Fox News contributor Topic: Pope Leo speaks out on AISee omnystudio.com/listener for privacy information.

34:07- Chris Swecker, attorney who served as assistant director of the FBI for the Criminal Investigative Division from 2004 to 2006 Topic: Three killed in San Diego Islamic Center shooting 46:50- John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: Primaries today; Luigi Mangione; Other news of the day 57:08- Chris Aviles, Founder and President of Garden State Esports Topic: Ocean County Spotlight 1:06:19- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: President Trump postponing his scheduled attack on Iran 1:18:20- David Fischer, CEO of Landmark Capital Topic: Inflation; Government debt; Other Gold news; David's limited-time offer 1:28:40- Alan Dershowitz, Harvard Law Professor Emeritus, host of "The DerShow," and the author of the new book "Could President Trump Constitutionally Serve a Third Term? My Nonpartisan Legal Analysis" Topic: Luigi Mangione; Alex Murdaugh; Other legal news of the day 1:40:43- Chris Grollnek, Retired Police Detective Corporal and Active Shooting Expert Topic: Three killed in San Diego Islamic Center shooting 1:53:18- Gianno Caldwell, Fox News Political Analyst, founder of the Caldwell Institute for Public Safety and the host of the "Outloud with Gianno Caldwell" podcast Topic: Jeanine Pirro's news conference on teen takeovers 2:03:09- Assemblyman Jake Blumencranz, Republican representing the 15th District of the New York State Assembly Topic: End of the LIRR strikeSee omnystudio.com/listener for privacy information.

37:52- John Solomon, award-winning investigative journalist, founder of “Just The News,” and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: Latest in the Virginia redistricting battle; Trump’s trip to Asia; Other news of the day 52:51- Thomas Homan, Border Czar for the Trump administration Topic: Kathy Hochul’s sanctuary policies 1:03:34- Danielle Kidney, Executive Director of the Brick Chamber of Commerce Topic: Businesses in Brick 1:11:52- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of “Revolution: Trump, Washington and ‘We The People’” Topic: Leadership in Iran; Trump’s summit with President Xi 1:26:04- David Fischer, CEO of Landmark Capital Topic: Jamie Dimon; U.S. Debt; David’s limited-time offer 1:45:31- Gregg Jarrett, Legal and political analyst for Fox News Channel and the author of “The Trial Of The Century” Topic: Suspected WHCD shooter pleads not guilty; Other legal news of the day 1:58:22- Brooke Goldstein, Executive Director of the Lawfare Project, Human Rights Attorney, and the author of “Lawfare: The War Against Free Speech” Topic: Netanyahu wants to draw U.S. financial support of Israel “down to zero”; Synagogue attacks in New YorkSee omnystudio.com/listener for privacy information.

37:00- Danny Coulson, Former Deputy Assistant Director of the FBI and Founding Commander of the FBI Hostage Rescue Team Topic: Investigating the WH Correspondents' Dinner shooting 51:27- Gen. Jack Keane, a retired 4-star general, the chairman of the Institute for the Study of War and Fox News Senior Strategic Analyst Topic: Trump dissatisfied with Iran's plan to reopen the Strait of Hormuz 1:27:09- David Fischer, CEO of Landmark Capital Topic: Push to revamp the Fed; Massive layoffs announced; Central Banks buying spree of Gold 1:46:58- Gregg Jarrett, Legal and political analyst for Fox News Channel and the author of "The Trial Of The Century" Topic: Suspected WH Correspondents' Dinner shooter charged on three counts; Jonathan Diller killer sentenced to 115 years in prison 2:00:17- Cristo Foufas, Broadcaster and royal commentator based in London Topic: King Charles and Queen Camilla's visit to the United States 2:11:57- Pastor Dave Watson, Senior Pastor of Calvary Chapel on Staten Island, Founder and President of the New York Institute of Biblical Studies, and the host of "God in Our City" on WMCA Topic: Latest assassination attempt against President Trump; Legalizing injustice and sin; The purpose of prayerSee omnystudio.com/listener for privacy information.

35:44- Gen. Jack Keane, a retired 4-star general, the chairman of the Institute for the Study of War and Fox News Senior Strategic Analyst Topic: Latest in Iran; Strait of Hormuz 49:21- John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: Sen. Rick Scott introduces legislation to repudiate Trump's 2019 impeachment; Other news of the day 59:38- Vincent J. Vallelong, President of the Sergeants Benevolent Association Topic: Sgt. Erik Duran released on bail 1:24:53- David Fischer, CEO of Landmark Capital Topic: Gold & silver vs. stock indexes; David's limited time offer to investors 1:36:03- Gordon Chang, Asia expert, columnist and author of "China is Going to War" Topic: U.S. Navy seizes Iranian ship linked to Chinese trade route; China's continued role in the Iran war 2:01:50- Miranda Devine, columnist for the New York Post and the author of "The Big Guy" Topic: "Trump tells The Post what he wants to do at Penn Station" (New York Post op ed) 2:12:13- Hans von Spakovsky, Senior Legal Fellow in the new Edwin Meese III Institute for the Rule of Law at Advancing American Freedom Topic: Kash Patel's $250 million defamation suit against The Atlantic; Legal news of the daySee omnystudio.com/listener for privacy information.

37:19- Hogan Gidley, Former National Press Secretary for the Trump campaign and former White House Deputy Press Secretary Topic: President Trump vs Pope Leo 52:38- Matthew "Whiz" Buckley, decorated former U.S. Navy F/A-18 Hornet pilot, TOP GUN graduate, and now the founder of the No Fallen Heroes Foundation Topic: Military blockade on Iranian ports 1:10:32- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: How Trump flipped the script on Iran 1:24:30- David Fischer, CEO of Landmark Capital Topic: France selling 129 tons of gold; Latest in gold and silver markets 1:46:23- Larry Elder, host of "The Larry Elder Show" on the Salem Radio Network, author of "As Goes California: My Mission to Rescue the Golden State and Save the Nation" and the host of the "We’ve Got A Country to Save" podcast Topic: Eric Swalwell's resignation 1:58:53- Marc Morano, Former Senior Staff Member of the Senate Environment & Public Works Committee, publisher of ClimateDepot.com, and the author of "The Great Reset: Global Elites and the Permanent Lockdown" Topic: How COVID hysteria killed off climate hysteria; Keynote speech at the D.C. Climate summit 2:07:51- Raymond Arroyo, managing editor & host of "The World Over" on EWTN, host of the "Arroyo Grande" podcast, and a Fox News contributor Topic: President Trump vs Pope LeoSee omnystudio.com/listener for privacy information.

35:28- Gen. Jack Keane, a retired 4-star general, the chairman of the Institute for the Study of War and Fox News Senior Strategic Analyst Topic: Iran's rejection of ceasefire deal; Airman rescue mission; President Trump's press conference yesterday 49:08- John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: Trump's press conference; DOJ to probe Mayor Mamdani's racial equity plan; Other news of the day 1:09:27- Gordon Chang, Asia expert, columnist and author of "China is Going to War" Topic: Possibility of China targeting the U.S. homeland if Iran War escalates 1:22:22- David Fischer, CEO of Landmark Capital Topic: Investing amid the war; Report from the Committee for a Responsible Budget 1:57:03- Dr. Tom Jones, PhD planetary scientist, pilot, veteran NASA astronaut who flew four space shuttle missions, and the author of "Space Shuttle Stories" Topic: Latest on the Artemis II mission 2:05:30- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: Latest in Iran and the Middle EastSee omnystudio.com/listener for privacy information.

49:52- Gen. Jack Keane, a retired 4-star general, the chairman of the Institute for the Study of War and Fox News Senior Strategic Analyst Topic: Iran War and ongoing negotiations 1:00:53- Gordon Chang, Asia expert, columnist and author of "China is Going to War" Topic: Cooperation between China and Russia amid Iran conflict 1:25:36- David Fischer, CEO of Landmark Capital Topic: Possibility of a recession; Iran attempting to disrupt the treasury market 1:36:41- Hans von Spakovsky, Senior Legal Fellow in the new Edwin Meese III Institute for the Rule of Law at Advancing American Freedom Topic: The legality of birthright citizenship 1:46:52- Dr. Nicole Saphier, board-certified radiologist, medical contributor for Fox News, and author of “Love, Mom: Inspiring Stories Celebrating Motherhood” Topic: Tuberculosis cases rising in the U.S. 2:07:55- Marty Resnick, Producer of "Stop the Ignorance: The Beauty That is New Jersey" Topic: His documentary short filmSee omnystudio.com/listener for privacy information.

32:58- Gen. Jack Keane, a retired 4-star general, the chairman of the Institute for the Study of War and Fox News Senior Strategic Analyst Topic: President Trump's dealing with Iran to end the war 42:24- Charley Pereira, Former National Transportation Safety Board investigator Topic: Investigation of the Air Canada crash at LaGuardia 1:05:39- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: Trump's negotiations with Iran 1:20:40- David Fischer, CEO of Landmark Capital Topic: Fed not lowering rates and the impact of de-dollarization on Gold and Silver 1:31:19- Kyle Bailey, Aviation analyst, pilot, former FAA Safety Team representative, and the author of "Witness: JFK Jr.'s Fatal Flight" Topic: Latest information on the LaGuardia Air Canada crash 2:09:06- Joseph diGenova, former U.S. Attorney for the District of Columbia Topic: SCOTUS and the future of mail-in ballots; Other legal news of the day 9:40- Raymond Arroyo, managing editor & host of "The World Over" on EWTN, host of the "Arroyo Grande" podcast, and a Fox News contributor Topic: Exorcists asking the Pope for "reinforcements" with demonic and cult activity on the riseSee omnystudio.com/listener for privacy information.

23:33- Joe Borelli, Former New York City Councilman and Managing Director of Chartwell Strategy GroupTopic: Stuck in Ireland on St. Patrick's Day 35:07- Lt. Col. Robert Maginnis, a retired U.S. Army officer and an experienced military analyst with on-the-ground experience inside Russia and Ukraine and the author of "Preparing for World War III" Topic: "Iran war success gives president a Trump card to play in China meeting" (Fox News op ed) 49:17- Congressman Mike Lawler, Republican representing New York's 17th Congressional District Topic: Celebrating St. Patrick's Day 1:00:48- Dr. Betsy McCaughey, New York Post columnist, former Lt. Gov. of NY State, Chairwoman and founder of the Committee to Reduce Infection DeathsTopic: Safety in New York amid Iran war; St. Patrick's Day 1:10:10- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: Europe's role in the Iranian conflict 1:23:33- David Fischer, CEO of Landmark Capital Topic: Strait of Hormuz; Oil; U.S. spending 1:36:47- Keeley Giblin, Former Production Intern on "The Joe Piscopo Show" Topic: Playing the bagpipes in the New York City St. Patrick's Day Parade today 1:45:36- Rich Lowry, Editor of the National Review and the author of "The Case for Nationalism" Topic: "Trump is obliterating Obama’s Iran-appeasement plan — to America’s benefit" (New York Post op ed) 2:06:08- Commissioner Ray Kelly, the longest-serving Commissioner of the NYPD in history who was in charge of the Secret Service during his tenure as Deputy Treasury Secretary under President Clinton Topic: St. Patrick's Day and the Irish heritage in the NYPDSee omnystudio.com/listener for privacy information.

Lt. Col. Robert Maginnis, a retired U.S. Army officer and an experienced military analyst with on-the-ground experience inside Russia and Ukraine and the author of "Preparing for World War III"Topic: Latest on the war in Iran Sgt. Joseph Imperatrice, Founder of Blue Lives Matter NYC with 19 years of law enforcement experience primarily in the Detective Bureau fieldTopic: Man accused of killing Jonathan Diller in court; IED incident David Fischer, CEO of Landmark CapitalTopic: Iran War and its impact on gold; Global spending Arthur Lih, Inventor & CEO of LifeVac and the author of "Sorry, Can't is a Lie"Topic: Latest from LifeVac Hans von Spakovsky, Senior Legal Fellow in the new Edwin Meese III Institute for the Rule of Law at Advancing American FreedomTopic: Judge blocks Fani Willis from fighting $17 million in Trump prosecution John McLaughlin, CEO of McLaughlin & Associates who was a pollster for former President Donald TrumpTopic: Polls amid Iran War Dr. Ben Dworkin, Founding Director of the Rowan Institute for Public Policy & Citizenship at Rowan University in Glassboro, NJTopic: NJ BudgetSee omnystudio.com/listener for privacy information.

John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice networkTopic: Trump and Netanyahu to meet Wednesday; Chinese scientists embraced by U.S. colleges; House passes major housing package, other news of the day Rob Chadwick, Retired FBI Supervisory Special Agent and Former Director of Tactical Training in Quantico and the Principal Training Advisor to the United States Concealed Carry Association (USCCA)Topic: Latest on the Nancy Guthrie investigation Art Del Cueto, Border Security Advisor for the Federation for American Immigration Reform (FAIR) and a 21-year veteran of the Border PatrolTopic: Federal judge in California blocks California law forcing ICE agents to remove masks during operations David Fischer, CEO of Landmark CapitalTopic: AI and how it can affect the economy and the stock market; China and the U.S. dollar; Gold and silver news Dr. Marc Siegel, physician, Professor of Medicine at the NYU Langone Medical Center, author of "The Miracles Among Us," and contributor to Fox NewsTopic: Latest in the MAHA movement; Nancy Guthrie's health concerns amid disappearance; Trump combating addiction; 18th person found dead from the cold in New York Marc Morano, Former Senior Staff Member of the Senate Environment & Public Works Committee, publisher of ClimateDepot.com, and the author of "The Great Reset: Global Elites and the Permanent Lockdown"Topic: Trump's ongoing fight against climate regulation; Judicial research center cuts climate section from judges' manualSee omnystudio.com/listener for privacy information.

What happens when a rare disease diagnosis turns life upside down? In this episode of Sounds of Science, host Mary Parker sits down with Bo Bigelow, Amber Freed, and David Fischer to explore the breakthroughs, challenges, and human stories behind Hao-Fountain Syndrome. From a father's fight for his daughter Tess to cutting-edge drug repurposing screens, discover how science, advocacy, and community are rewriting the future for families worldwide. Show NotesRare Disease | Charles River Vital Science Podcast: Strength in Numbers Rare Disease Research for Drug Development Foundation for USP-7 Related Diseases Stronger Every Day Podcast 

Zu Gast sind David und Jonas Fischer, die unter anderem Spielanalysen für TV-Experten bei Sky Austria und Sky Deutschland erstellen. Gemeinsam analysieren wir den Einwurf nicht als „Ball wieder ins Spiel bringen“, sondern als taktisches Werkzeug. Wir sprechen über verschiedene Einwurfarten, häufige Fehlerbilder, konkrete Potenziale sowie Trainings- und Spielformen, mit denen Einwürfe systematisch verbessert werden können – vom schnellen Einwurf bis zur Spielverlagerung unter Gegnerdruck.

See omnystudio.com/listener for privacy information.

Joe Piscopo will be departing at 8 a.m. Al Gattullo and Joe Sibilia will take over for the remainder of the show. 25:13- Jeff James, Retired Assistant Special Agent in Charge with the U.S. Secret Service Topic: Volunteer radio host's directive to kill JD Vance 38:56- John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: Iran; Jack Smith to testify before House Judiciary Committee on January 22; State of the State addresses today; Other news of the day 51:15- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'.” Topic: Iran, Trump, and Maduro 1:03:08- David Fischer, CEO of Landmark Capital Topic: Why gold and silver will outperform stock indexes 1:28:34- Dr. Ben Dworkin, Founding Director of the Rowan Institute for Public Policy & Citizenship at Rowan University in Glassboro, NJ Topic: Phil Murphy's final State of the State address 2:04:38- Dr. Rebecca Grant, national security analyst based in Washington, D.C., specializing in defense and aerospace research, founder of IRIS Independent Research, and Senior Fellow at the Lexington Institute Topic: Possibility of an attack on Iran 2:13:02- Lt. Col. Chuck DeVore (Ret.), Former National Guardsman and Chief National Initiatives Officer at the Texas Public Policy Foundation, who served as a Republican member of the California State Assembly from 2004 to 2010 Topic: "Left seeks martyrs to fuel anti-Trump uprising as ICE enforcement operations ramp up nationwide" (Fox News op ed)See omnystudio.com/listener for privacy information.

41:47- Col. Kurt Schlichter, Attorney, Retired Army Infantry Colonel with a Masters in Strategic Studies from the United States Army War College, Senior Columnist at Town Hall, and the author of the new book "Panama Red" Topic: Military operation in Venezuela and Maduro's court appearance 55:25- Corey Lewandowski, Trump 2024 Senior Official Topic: Trump's capture of Maduro 1:16:31- Nicole Parker, Special Agent with the FBI from 2010 through October 2022, Fox News contributor, and the author of "The Two FBIs: The Bravery and Betrayal I Saw in My Time at the Bureau" Topic: FBI's role in Venezuela raid and Maduro's capture, Tim Walz 1:31:43- David Fischer, CEO of Landmark Capital Topic: Market reaction to Maduro; Predictions for 2026 1:41:41- Thomas Homan, Border Czar for the Trump administration Topic: ICE agents hotel reservations allegedly canceled in Minnesota, Maduro 2:10:37- Alan Dershowitz, Harvard Law Professor Emeritus, host of "The DerShow," and the author of "The Ten Big Anti-Israel Lies: And How to Refute Them with Truth" and the new book "The Preventative State" Topic: Maduro's court appearance; Accusations of antisemitism against Zohran MamdaniSee omnystudio.com/listener for privacy information.

The animated hit movie 'David' captures David's rise from shepherd boy to warrior, and, ultimately, unifier of a kingdom. David's story begins in quiet devotion, from the songs of his mother to the whispers of a faithful God. When the giant Goliath rises to terrorize a nation, the young shepherd armed with only a sling, a few stones, and an unshakable faith steps forward to become a hero. FOX's Ryan Schmelz speaks with Brian Stivale, the actor who plays 'Samuel' in 'David', and David Fischer, director of acquisitions and business affairs at 'Angel Studios', who both share how proud they are of the series and believe family-friendly and faith-based productions have a growing audience that is here to stay. FOX's Ryan Schmelz speaks with Brian Stivale, the actor who plays 'Samuel' in 'David', and David Fischer, director of acquisitions and business affairs at 'Angel Studios', who both share how proud they are of the series and believe family-friendly and faith-based productions have a growing audience that is here to stay. Click Here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ To Follow 'The FOX News Rundown: Evening Edition' Learn more about your ad choices. Visit podcastchoices.com/adchoices

The animated hit movie 'David' captures David's rise from shepherd boy to warrior, and, ultimately, unifier of a kingdom. David's story begins in quiet devotion, from the songs of his mother to the whispers of a faithful God. When the giant Goliath rises to terrorize a nation, the young shepherd armed with only a sling, a few stones, and an unshakable faith steps forward to become a hero. FOX's Ryan Schmelz speaks with Brian Stivale, the actor who plays 'Samuel' in 'David', and David Fischer, director of acquisitions and business affairs at 'Angel Studios', who both share how proud they are of the series and believe family-friendly and faith-based productions have a growing audience that is here to stay. FOX's Ryan Schmelz speaks with Brian Stivale, the actor who plays 'Samuel' in 'David', and David Fischer, director of acquisitions and business affairs at 'Angel Studios', who both share how proud they are of the series and believe family-friendly and faith-based productions have a growing audience that is here to stay. Click Here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ To Follow 'The FOX News Rundown: Evening Edition' Learn more about your ad choices. Visit podcastchoices.com/adchoices

The animated hit movie 'David' captures David's rise from shepherd boy to warrior, and, ultimately, unifier of a kingdom. David's story begins in quiet devotion, from the songs of his mother to the whispers of a faithful God. When the giant Goliath rises to terrorize a nation, the young shepherd armed with only a sling, a few stones, and an unshakable faith steps forward to become a hero. FOX's Ryan Schmelz speaks with Brian Stivale, the actor who plays 'Samuel' in 'David', and David Fischer, director of acquisitions and business affairs at 'Angel Studios', who both share how proud they are of the series and believe family-friendly and faith-based productions have a growing audience that is here to stay. FOX's Ryan Schmelz speaks with Brian Stivale, the actor who plays 'Samuel' in 'David', and David Fischer, director of acquisitions and business affairs at 'Angel Studios', who both share how proud they are of the series and believe family-friendly and faith-based productions have a growing audience that is here to stay. Click Here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ To Follow 'The FOX News Rundown: Evening Edition' Learn more about your ad choices. Visit podcastchoices.com/adchoices

37:20- John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: Rob Reiner; Trump suing the BBC for $10 billion Bondi Beach massacre, other news of the day 51:01- Rob Chadwick, Retired FBI Supervisory Special Agent and Former Director of Tactical Training in Quantico and the Head of Personal and Public Safety for the United States Concealed Carry Association (USCCA) Topic: Search for the Brown University shooter; FBI thwarts Los Angeles New Year's Eve bomb plot 1:00:22- Rob Reiner Interview (2016), Joe revisits an interview he had with the late Rob Reiner back in May 2016. 1:11:16- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'.” Topic: Oil tanker, Australia, latest in Venezuela 1:24:40- David Fischer, CEO of Landmark Capital Topic: President Trump pushing for lower interest rates 1:35:26- Arthur Aidala, former Brooklyn Prosecutor, star criminal defense attorney, and host of "The Arthur Aidala Power Hour" weeknights at 6 p.m. on AM 970 The Answer Topic: Nick Reiner charged with murder 2:02:15- Alan Dershowitz, Harvard Law Professor Emeritus, host of "The DerShow," and the author of "The Ten Big Anti-Israel Lies: And How to Refute Them with Truth" and the new book "The Preventive State." Topic: Australia Hanukkah shooting, Nick Reiner charged with murder 2:10:34- Patrick J. Brosnan, Retired and Decorated NYPD Detective and the host of "Pat Brosnan: Live From the Batcave" Saturdays at 9 a.m. on AM 970 The Answer Topic: Death of Rob Reiner, security issues at Brown University, Australia shootingSee omnystudio.com/listener for privacy information.

Know the saying "So much to do and so little time"? Today's show is exactly that! With only half the time Simon fits in just as much local news and information! Simon begins by talking about the Holliwell Covered Bridge of Bridges of Madison County fame and it's dire need for construction help! An Iowa icon needs an Iowa Nice miracle! Next, Simon talks Christmas at Terrace Hill with Molly Franta that will be honoring the families of deployed troops here in Iowa. Then, he talks to Allison Hanner about the upcoming Variety Children's Charity of Iowa Radiothon over the next few days. And finally, Simon talks to financial expert David Fischer from Landmark Capital about today's rate cut by the U.S. Federal Reserve. What does this mean for your wallet and financial future? All this and more!!!

53:12- Daniel Hoffman, Ret. CIA Senior Clandestine Services Officer and a Fox News ContributorTopic: Zelenskyy's meeting in London 1:03:08- Col. Patrick Callahan, New Jersey State Police Superintendent and State Director of Emergency Management Topic: His retirement announcement 1:13:48- Lt. Col. Chuck DeVore (Ret.), Former National Guardsman and Chief National Initiatives Officer at the Texas Public Policy Foundation who served as a Republican member of the California State Assembly from 2004 to 2010 Topic: Congress moving to block the Pentagon from cutting troops in Europe and South Korea 1:28:22- David Fischer, CEO of Landmark Capital Topic: Fed ending biggest liquidity drain in history 1:38:02- Col. Kurt Schlichter, Attorney, Retired Army Infantry Colonel with a Masters in Strategic Studies from the United States Army War College, Senior Columnist at Town Hall, and the author of the new book "Panama Red" Topic: His new book 1:51:14- Dr. Nicole Saphier, board-certified radiologist, medical contributor for Fox News, and author of “Love, Mom: Inspiring Stories Celebrating Motherhood” Topic: RFK Jr. announcing plans to make flights healthier 2:05:20- Joseph diGenova, former U.S. Attorney for the District of Columbia Topic: Alina Habba's resignation as New Jersey U.S. AttorneySee omnystudio.com/listener for privacy information.

Simon talks to Tim Marden from The John Birch Society about the bill introduced by Senator Bernie Moreno (Ohio) who wants a ban on Dual Citizenship. What do you think - should new citizens "pick a side" prior to their oath? Later, Simon gets this week's financial update from David Fischer from Landmark Capital. What's happening with Bitcoin, Stocks and the markets? Are we about to enter a Bear Market on a bubble? Listen and FIND OUT if your wallet is about to get fatter or thinner!

The Joe Piscopo Show 12-2-25 24:23- Col. Patrick Callahan, New Jersey State Police Superintendent and State Director of Emergency Management Topic: Preparations for impending Nor'Easter, road conditions 37:07- Joseph diGenova, former U.S. Attorney for the District of Columbia Topic: Appeals court upholds ruling disqualifying Alina Habba 52:21- John Solomon, award-winning investigative journalist, founder of "Just The News," and the host of “Just the News, No Noise” on the Real America’s Voice network Topic: White House confirming Pete Hegseth authorized second strike on drug boat, Homeland Security 1:13:41- Matt Rooney, Founder and Editor-in-Chief of SaveJersey.com Topic: Alina Habba 1:27:36- David Fischer, CEO of Landmark Capital Topic: Possibility of a looming bear market, U.S. Treasury reporting October budget, Federal Reserve 2% inflation target and the impact on gold and silver prices 1:38:04- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: U.S. relations with Venezuela, second strike on drug boat, latest with Russia-Ukraine peace negotiations 1:49:49- Dr. Marc Siegel, physician, Professor of Medicine at the NYU Langone Medical Center, author of "The Miracles Among Us," and contributor to Fox News Topic: President Trump's MRI, his new book 2:03:59- Arthur Aidala, former Brooklyn Prosecutor, star criminal defense attorney, and host of "The Arthur Aidala Power Hour" weeknights at 6 p.m. on AM 970 The Answer Topic: Luigi Mangione pretrial hearings on evidence in the death of UnitedHealthcare CEO Brian ThompsonSee omnystudio.com/listener for privacy information.

The Joe Piscopo Show 11-25-25 25:52- Joseph diGenova, former U.S. Attorney for the District of Columbia Topic: James Comey and Letitia James indictments dismissed 38:52- Gen. Jack Keane, a retired 4-star general, the chairman of the Institute for the Study of War and Fox News Senior Strategic Analyst Topic: Possibility of Venezuela covert actions beginning in the near future 1:03:21- Steve Sansone, Commissioner of the Department of Parks in Yonkers NY Topic: Celebrating Yonkers 1:12:44- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: Backing Trump's nationwide ICE raids 1:25:36- David Fischer, CEO of Landmark Capital Topic: Are food prices higher or lower this year? 1:48:00- Gregg Jarrett, Legal and political analyst for Fox News Channel and the author of "The Trial Of The Century"Topic: James Comey and Letitia James indictments dismissed 2:03:33- Chris Swecker, attorney who served as assistant director of the FBI for the Criminal Investigative Division from 2004 to 2006 Topic: FBI's missed opportunities to stop Thomas Crooks in attempted Trump assassination 2:13:27- Kyle Bailey, Aviation analyst, pilot, and former FAA Safety Team representative Topic: Thanksgiving travel, Venezuela flights canceled following FAA security warning See omnystudio.com/listener for privacy information.

Harvard Professor of Science and Astronomer, Dr Avi Loeb, talks to Simon about one of his most favorite topics - SPACE - specifically the anomalies of the 3I/ATLAS comet. It's the size of Manhattan, has anomalies unlike anything we've seen before and has scientist across the globe puzzled. What could it possibly be??? Later, Simon talks to David Fischer from Landmark Capital for his snapshot of today's financials and the economy, including the revaluing of gold and silver. How will this affect your pockets; will they become lighter or heavy enough to hold you down???

Hogan Gidley, Former National Press Secretary for the Trump campaign and former White House Deputy Press SecretaryTopic: Trump at the McDonald's Impact Summit, $2,000 tariff dividends, other news from the White House K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'”Topic: Greece and Ukraine gas deal, Trump warning he will launch strikes against Mexico Besarta Sinanaj, Marketing Director, Benjamin Restaurant GroupTopic: Celebrating Yonkers Joseph diGenova, former U.S. Attorney for the District of ColumbiaTopic: Epstein files, Judge orders DOJ to give Comey grand jury records David Fischer, CEO of Landmark CapitalTopic: Stable coins, U.S. government debt, U.S. treasury real values Lt. Col. Robert Maginnis, a retired U.S. Army officer and an experienced military analyst with on-the-ground experience inside Russia and Ukraine and the author of "Preparing for World War III"Topic: Possibility of strikes on Mexico, Russia strike on Odesa Arthur Lih, Inventor & CEO of LifeVac and the author of "Sorry, Can't is a Lie"Topic: 5,000 lives savedSee omnystudio.com/listener for privacy information.

35:49- Kieran Lalor, USMC Iraq Vet, Founder of Iraq Vets for Congress, and Former New York State Assemblyman Topic: Veterans Day 48:11- Hogan Gidley, Former National Press Secretary for the Trump campaign and former White House Deputy Press Secretary Topic: Trump's response to the government shutdown 1:10:07- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: Trump's Syria play 1:23:28- David Fischer, CEO of Landmark Capital Topic: BRICS meeting, Government revaluation of gold, government moving towards a Gold Revaluation, How to roll over your 401k or transfer your IRA into physical Gold and Silver 1:34:05- Joseph diGenova, former U.S. Attorney for the District of Columbia Topic: SCOTUS declines to revisit same-sex marriage decision, Trump pardons, legality of tariffs 1:46:03- Lt. Col. Robert Maginnis, a retired U.S. Army officer and an experienced military analyst with on-the-ground experience inside Russia and Ukraine and the author of "Preparing for World War III" Topic: Veteran's Day 1:58:50- Col. Jack Jacobs, a retired colonel in the United States Army and a Medal of Honor recipient for his actions during the Vietnam War Topic: Veterans Day 2:07:57- Bruce Blakeman, Nassau County Executive Topic: Reelection victorySee omnystudio.com/listener for privacy information.

Dynamo Dresden hat sich von Sportgeschäftsführer Thomas Brendel getrennt – nur sechs Wochen nach dem Abschied von Geschäftsführer David Fischer. In dieser Sonderfolge analysieren Jens Umbreit und Tino Meyer gemeinsam mit Journalist und Dynamo-Kenner Uwe Karte die Hintergründe der Entscheidung, den Zeitpunkt und die Folgen für den Verein. Im Mittelpunkt stehen die Spannungen zwischen Brendel und Trainer Thomas Stamm, die Rolle des Aufsichtsrats und die Frage, wie Dynamo sportlich und strukturell wieder zur Ruhe kommen kann. Außerdem geht es um die sportliche Lage nach dem Nürnberg-Spiel und die Aussichten bis zur Winterpause.

36:05- Assemblyman Dov Hikind, former New York State Assemblyman and the son of holocaust survivors Topic: Antisemitism watchdog report on Mamdani 49:50- Mike Kelly, columnist for The Bergen Record/NorthJersey.com Topic: Why Mikie Sherrill isn't dominating in the New Jersey race 1:01:09- Will La Salle, Independent Filmmaker and Founder of LaSalle ProductionsTopic: Celebrating Yonkers 1:10:50- K.T. McFarland, Former Trump Deputy National Security Advisor and the author of "Revolution: Trump, Washington and 'We The People'” Topic: Trump's continued military attacks on alleged drug boats 1:23:54- David Fischer, CEO of Landmark Capital Topic: Federal Reserve interest rate, Trump administration revaluing gold 1:34:32- Hogan Gidley, Former National Press Secretary for the Trump campaign and former White House Deputy Press Secretary Topic: Trump's endorsements on Election Day 1:47:36- Steve Forbes, Chairman and Editor-in-Chief at Forbes Media & the co-author of "Inflation: What It Is, Why It's Bad, and How to Fix It" Topic: The future of Wall Street under a Mamdani administration 2:02:21- Miranda Devine, columnist for the New York Post and the author of "The Big Guy" Topic: Election Day, "John Brennan’s unhinged blowup over ‘Dirty 51’ letter, Hunter Biden laptop shows he’s worried" (New York Post op ed) 2:15:14- Maud Maron, Republican Candidate for Manhattan District Attorney Topic: Her campaign against Alvin BraggSee omnystudio.com/listener for privacy information.

Simon talks to Democratic candidate for Governor and current Iowa State Auditor, Rob Sand, live in studio. He hates D.C. and the 2-party system, he wants to be Iowa's biggest cheerleader and a "cheerleader for truth'. He wants voting reform and likes an approval voting system over ranked choice voting. Later, Simon gets the latest in financial info from David Fischer with Landmark Capital including gold and silver markets.

Simon talks to Maureen Steele, co-founder of 'American Made Foundation', about the outrageous nightmare one family is living over their cancer patient son. Despite documented proof of his treatments CPS is now involved and their lives have been turned upside down. You won't believe this story! Later, Simon talks money, finance and the economy with David Fischer from Landmark Capital. Is the economy slowing? Do you have enough gold & silver? What effects will today's announcement from the US Treasury Secretary have on the markets?

Simon talks to childhood cancer patient Mya and her Mom Brooke about her charity MyaStrong and how she's doing now through treatment. Later, Simon talks to Bill Dendy for a financial update and government shutdown and David Fischer from Landmark Capital about the current outlook of investments

Ryan Routh, the man charged with trying to kill Donald Trump at his Florida golf club last year, was convicted on five charges, including attempted assassination, assaulting a federal officer and possession of a firearm. Routh could face life in prison when he is sentenced in December. Geoff Bennett discussed the case with David Fischer of the Associated Press. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

AP correspondent David Fischer reports from Fort Pierce, Florida, where the man charged with hiding at a golf course to attempt to kill President Trump presents his defense today.

„Nur weil ich Geld habe, bedeutet das nicht, dass ich mich verarschen lasse.“ Mit diesem Satz bringt David Fischer, Founder von Highsnobiety, die Krise der Luxusbranche auf den Punkt. Im TOMorrow Podcast sagt er, was Marken und Markenmacher jetzt verstehen müssen. 20 Jahre Highsnobiety: Vom Sneaker-Blog zur globalen 200 Mio. € Brand, Consulting-Firma und Fashionplattform. Zum Jubliäum hat er in Zusammenarbeit mit Boston Consulting den Luxury Report 2025 herausgebracht. Die bittere Wahrheit: Neu ist nicht mehr relevant. Zitat des Tages: „Stop Selling the Dream. Start Fitting Into Reality.“ Für wen ist diese Folge ein Must-Hear? CMOs, Brand Manager, Kreative, Consultants, Luxury Marketers, Gründer, Studierende im Bereich Fashion, Marketing & Business. Alle, die wissen wollen, wie man in einer Welt nach dem „Peak Luxury“ noch Relevanz erzeugt. Warum du reinhören musst: Diese Folge ist dein Deep Dive in die Zukunft des Luxus. In Zeiten von Fast Fashion, KI-Designs und Marketing-Gimmicks brauchst du ein neues Playbook. David Fischer liefert es – direkt aus dem Highsnobiety-HQ in Berlin. Learning: Seine krasse Founder-Story. Wie Streetwear wirklich zur neuen Couture wurde. Was gerade bei Luxus-Gigant LVMH passiert – und warum ein Kulturwandel unausweichlich ist Buch-Tipp: The Complete Highsnobiety Guide to Creative Collaborations“.

Podcast Episode Description: “Money Monday with Kevin McCullough: Oil, Gold & Turnaround Stocks” This week on Money Monday, Kevin McCullough dives deep into the market impact of the latest geopolitical developments and economic trends with three top financial experts. • Lou Basenese breaks down how oil markets are reacting to Trump's Houthi offensive and what it means for energy stocks. • David Fischer provides expert insights into the gold market's response to global uncertainty and why investors are turning to precious metals. • Hilary Kramer highlights turnaround stocks that could present major investment opportunities in today's market. If you're looking for actionable insights on the biggest financial moves, this episode is a must-listen! Listen now on Apple Podcasts, Spotify, and SoundCloud!

Dr. Neeraj Agarwal and Dr. Peter Hoskin discuss key abstracts in GU cancers from the 2025 ASCO Genitourinary Cancers Symposium, including novel therapies in prostate, bladder, and kidney cancer and the impact of combination therapies on patient outcomes. TRANSCSRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program and professor of medicine at the Huntsman Cancer Institute at the University of Utah, and editor-in-chief of ASCO Daily News. Today, we'll be discussing practice-informing abstracts and other key advances in GU oncology featured at the 2025 ASCO Genitourinary Cancers Symposium. Joining me for this discussion is Dr. Peter Hoskin, the chair of this year's ASCO GU Symposium. Dr. Hoskin is a professor in clinical oncology in the University of Manchester and honorary consultant in clinical oncology at the Christie Hospital, Manchester, and University College Hospital London, in the United Kingdom. Our full disclosures are available in the transcript of this episode. Peter, thank you for joining us today. Dr. Peter Hoskin: Thank you so much, Neeraj. I am very pleased to be here. Dr. Neeraj Agarwal: The GU meeting highlighted remarkable advancements across the spectrum of GU malignancies. What stood out to you as the most exciting developments at the ASCO GU Symposium?  Dr. Peter Hoskin: The theme of this year's meeting was "Driving Innovation, Improving Patient Care," and this reflected ASCO GU's incredible milestone in GU cancer research over the years. We were thrilled to welcome almost 6,000 attendees on this occasion from over 70 countries, and most of them were attending in person and not online, although this was a hybrid meeting. Furthermore, we had more than 1,000 abstract submissions. You can imagine then that it fostered fantastic networking opportunities and facilitated valuable knowledge and idea exchanges among experts, trainees, and mentees. So, to start I'd like to come back to you for a second because the first day started with a focus on prostate cancer and some of the key clinical trials. And congratulations to you, Neeraj, on sharing the data from the TALAPRO-2 trial, which we were eagerly awaiting. I'd love to get your thoughts on the data that you presented. Could you tell us more about that trial, Abstract LBA18?  Dr. Neeraj Agarwal: Yes, Peter, I agree with you. It was such an exciting conference overall and thank you for your leadership of this conference. So, let's talk about the TALAPRO-2 trial. First of all, I would like to remind our audience that the combination of talazoparib plus enzalutamide was approved by the U.S. FDA in June 2023 in patients with metastatic castration-resistant prostate cancer harboring HRR gene alterations, after this combination improved the primary endpoint of radiographic progression-free survival compared to enzalutamide alone in the randomized, double-blind, placebo-controlled, multi-cohort phase 3 TALAPRO-2 trial. In the abstract I presented at ASCO GU 2025, we reported the final overall survival data, which was a key alpha-protected secondary endpoint in cohort 1, which enrolled an all-comer population of patients with mCRPC. So, at a median follow-up of around 53 months, in the intention-to-treat population, the combination of talazoparib plus enzalutamide significantly reduced the risk of death by 20% compared to enzalutamide alone, with a median OS of 45.8 months in the experimental arm versus 37 months in the control arm, which was an active control arm of enzalutamide. This improvement was consistent in patients with HRR alterations with a hazard ratio of 0.54 and in those with non-deficient or unknown HRR status, with a hazard ratio of 0.87. In a post hoc analysis, the hazard ratio for OS was 0.78 favoring the combination in those patients who did not have any HRR gene alteration in their tumors by both tissue and ctDNA testing. Consistent with the primary analysis, the updated rPFS data also favored the experimental arm with a median rPFS of 33.1 compared to 19.5 months in the control arm, and a hazard ratio of 0.667. No new safety signals were identified with extended follow-up. Thus, TALAPRO-2 is the first PARP inhibitor plus ARPI study to show a statistically significant and a clinically meaningful improvement in OS compared to standard-of-care enzalutamide as first-line treatment in patients with mCRPC unselected for HRR gene alterations. Dr. Peter Hoskin: Thank you, Neeraj. That's a great summary of the data presented and very important data indeed. There was another abstract also featured in the same session, Abstract 20, titled “Which patients with metastatic hormone-sensitive prostate cancer benefit more from androgen receptor pathway inhibitors? STOPCAP meta-analyses of individual participant data.” Neeraj, could you tell us more about this abstract? Dr. Neeraj Agarwal: Absolutely, I would be delighted to. So, in this meta-analysis, Dr. David Fischer and colleagues pooled individual participant data from different randomized phase 3 trials in the mHSPC setting to assess the potential ARPI effect modifiers and determine who benefits more from an ARPI plus ADT doublet. The primary outcome was OS for main effects and PFS for subgroup analyses. Prostate cancer specific survival was a sensitivity outcome. The investigators pooled data from 11 ARPI trials and more than 11,000 patients. Overall, there was a clear benefit of adding an ARPI on both OS and PFS, with hazard ratios of 0.66 and 0.51, respectively, representing a 13% and 21% absolute improvement at 5 years, respectively, with no clear difference by the class of agent. When stratifying the patients by age group, the effects of adding an ARPI on OS and PFS were slightly smaller in patients older than 75, than in those younger than 65, or aged between 65 and 75 years. Notably, in the trials assessing the use of abiraterone, we saw very little OS effects in the group of patients older than 75, however there was some benefit maintained in prostate-cancer specific survival, suggesting that other causes of death may be having an impact. The effects of the other ARPIs, or ‘lutamides' as I would call them, were similar across all three age subgroups on both OS and PFS. Therefore, the majority of patients with mHSPC benefit from the addition of ARPIs, and the benefits/risks of abiraterone and other ‘amides' must be considered in older patients.  Dr. Peter Hoskin: Thanks, Neeraj. Another great summary relevant to our day-to-day practice. Of course, there's ongoing collection of individual patient data from other key trials, which will allow robust comparison of ARPI doublet with triplet therapy (including docetaxel), guiding more personalized treatment.   Dr. Neeraj Agarwal: I agree with you, Peter, we need more data to help guide personalized treatment for patients with mHSPC and potentially guide de-escalation versus escalation strategies. Now, moving on to a different setting in prostate cancer, would you like to mention Abstract 17 titled, “Overall survival and quality of life with Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901),” presented by Dr. Louise Emmett? Dr. Peter Hoskin: Of course I will. So, ENZA-p was a multicenter, open-label, randomized, phase 2 trial conducted in Australia. It randomized 163 patients into adaptive doses (2 or 4 cycles) of Lu-PSMA-617 plus enzalutamide versus enzalutamide alone as first-line treatment in PSMA-PET-CT-positive, poor-risk, mCRPC. The interim analysis of ENZA-p with median follow-up 20 months showed improved PSA-progression-free survival with the addition of Lu-PSMA-617 to enzalutamide. Here, the investigators reported the secondary outcomes, overall survival, and health-related quality of life (HRQOL). After a median follow up of 34 months, overall survival was longer in the combination arm compared to the enzalutamide arm, with a median OS of 34 months compared to 26 months; with an HR of 0.55. Moreover, the combination improved both deterioration-free survival and health-related quality of life indicators for pain, fatigue, physical function, and overall health and quality of life compared to the control arm. Consistent with the primary analysis, the rPFS also favored the experimental arm with a median rPFS of 17 months compared to 14 months with a HR of 0.61. So, the addition of LuPSMA improved overall survival, and HRQOL in patients with high-risk mCRPC. Dr. Neeraj Agarwal: Thank you, Peter. Great summary, and promising results with Lu-177 and ARPI combination in first line treatment for mCRPC among patients who had two or more high risk features associated with early enzalutamide failure. Before we move on to bladder cancer, would you like to tell us about Abstract 15 titled, “World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration,” presented by Dr. Chad Tang?  Dr. Peter Hoskin: Sure. So, with metastatic-directed therapy (MDT), we have a number of phase 2 studies making up the database, and the X-MET collaboration aimed to consolidate all randomized data on oligometastatic solid tumors. This abstract presented pooled individual patient data from all the published trials involving patients with oligometastatic prostate cancer who received MDT alongside standard of care (SOC) against SOC alone. The analysis included data from five trials, encompassing 472 patients with oligometastatic prostate cancer, and followed for a median of 41 months. Patients were randomly assigned in a 1:1 ratio to receive either MDT plus SOC or SOC alone. The addition of MDT significantly improved PFS. The median PFS was 32 months with MDT compared to 14.9 months with SOC alone, with an HR of 0.45. Subgroup analyses further confirmed the consistent benefits of MDT across different patient groups. Regardless of factors like castration status, receipt of prior primary treatment, stage, or number of metastases, MDT consistently improved PFS. In patients with mHSPC, MDT significantly delayed the time to castration resistance by nine months, extending it to a median of 72 months compared to 63 months in the SOC group with an HR of 0.58. In terms of OS, the addition of MDT improved the 48-month survival rate by 12%, with OS rates of 87% in the MDT+SOC group compared to 75% in the SOC alone group. Dr. Neeraj Agarwal: Thank you, Peter. These data demonstrate that adding MDT to systemic therapy significantly improves PFS, rPFS, and castration resistance-free survival, reinforcing its potential role in the treatment of oligometastatic prostate cancer. So, let's switch gears to bladder cancer and start with Abstract 658 reporting the OS analysis of the CheckMate-274 trial. Would you like to tell us about this abstract?  Dr. Peter Hoskin: Yes, sure, Neeraj. This was presented by Dr. Matt Milowsky, and it was additional efficacy outcomes, including overall survival, from the CheckMate-274 trial which evaluated adjuvant nivolumab versus placebo in patients with high-risk muscle-invasive bladder cancer after radical surgery. The phase 3 trial previously demonstrated a significant improvement in disease-free survival with nivolumab. With a median follow-up of 36.1 months, disease-free survival was longer with nivolumab compared to placebo across all patients with muscle-invasive bladder cancer, reducing the risk of disease recurrence or death by 37%. Among patients who had received prior neoadjuvant cisplatin-based chemotherapy, nivolumab reduced this risk by 42%, whilst in those who had not received chemotherapy, the risk was reduced by 31%. Overall survival also favored nivolumab over placebo, reducing the risk of death by 30% in all patients with muscle-invasive bladder cancer and by 52% in those with tumors expressing PD-L1 at 1% or higher. Among patients who had received prior neoadjuvant chemotherapy, nivolumab reduced the risk of death by 26%, whilst in those who had not received chemotherapy, the risk was reduced by 33%. Alongside this, the safety profile remained consistent with previous findings. Dr. Neeraj Agarwal: Thank you, Peter, for such a nice overview of this abstract. These results reinforce adjuvant nivolumab as a standard of care for high-risk muscle-invasive bladder cancer, offering the potential for a curative outcome for our patients. Dr. Peter Hoskin: I agree with you Neeraj. Perhaps you would like to mention Abstract 659 titled, “Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.” Dr. Neeraj Agarwal: Of course. Dr. Galsky presented additional outcomes from the phase 3 NIAGARA study, which evaluated perioperative durvalumab combined with neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. The study previously demonstrated a significant improvement in event-free survival and overall survival with durvalumab compared to chemotherapy alone, with a manageable safety profile and no negative impact on the ability to undergo radical cystectomy. Among the 1,063 randomized patients, those who received durvalumab had a 33% reduction in the risk of developing distant metastases or death and a 31% reduction in the risk of dying from bladder cancer compared to those who received chemotherapy alone. More patients who received durvalumab achieved a pathological complete response at the time of surgery with 37% compared to 28% in the chemotherapy-alone group. Patients who achieved a pathological complete response had better event-free survival and overall survival compared to those who did not. In both groups, durvalumab provided additional survival benefits, reducing the risk of disease progression or death by 42% and the risk of death by 28% in patients with a pathological complete response, while in those patients without a pathological complete response, the risk of disease progression or death was reduced by 23% and the risk of death by 16% when durvalumab was added to the chemotherapy. Immune-mediated adverse events occurred in 21% of patients in the durvalumab group compared to 3% in the chemotherapy-alone group, with grade 3 or higher events occurring in 3% compared to 0.2%. The most common immune-related adverse events included hypothyroidism in 10% of patients treated with durvalumab compared to 1% in the chemotherapy-alone group, and hyperthyroidism in 3% versus 0.8%. At the time of the data cutoff, these adverse events had resolved in 41% of affected patients in the durvalumab group and 44% in the chemotherapy-alone group. Dr. Peter Hoskin: Thank you, Neeraj, for the great summary. These findings further support the role of perioperative durvalumab as a potential standard of care for patients with muscle-invasive bladder cancer. Dr. Neeraj Agarwal: I concur with your thoughts, Peter. Before wrapping up the bladder cancer section, would you like to mention Abstract 664 reporting updated results from the EV-302 trial, which evaluated enfortumab vedotin in combination with pembrolizumab compared to chemotherapy as first-line treatment for patients with previously untreated locally advanced or metastatic urothelial carcinoma? Dr. Peter Hoskin: Yes, of course. Dr. Tom Powles presented updated findings from the EV-302 study, and in this abstract presented 12 months of additional follow-up for EV-302 (>2 y of median follow-up) and an exploratory analysis of patients with confirmed complete response (cCR). The study had a median follow-up of 29.1 months and previously demonstrated significant improvements in progression-free survival and overall survival with enfortumab vedotin and pembrolizumab. This is now the standard of care in global treatment guidelines. Among the 886 randomized patients, enfortumab vedotin and pembrolizumab reduced the risk of disease progression or death by 52% and the risk of death by 49% compared to chemotherapy. The survival benefit was consistent regardless of cisplatin eligibility or the presence of liver metastases. The confirmed objective response rate was higher with enfortumab vedotin and pembrolizumab at 67.5% compared to 44.2% with chemotherapy. The median duration of response was 23.3 months with enfortumab vedotin and pembrolizumab compared to 7.0 months with chemotherapy. A complete response was achieved in 30.4% of patients in the enfortumab vedotin and pembrolizumab group compared to 14.5% in the chemotherapy group, with the median duration of complete response not yet reached in the enfortumab vedotin and pembrolizumab group compared to 15.2 months in the chemotherapy group. Severe treatment-related adverse events occurred in 57.3% of patients treated with enfortumab vedotin and pembrolizumab compared to 69.5% in the chemotherapy group, while in patients who achieved a complete response, severe adverse events occurred in 61.7% of those treated with enfortumab vedotin and pembrolizumab compared to 71.9% with chemotherapy. Treatment-related deaths were reported in 1.1% of patients treated with enfortumab vedotin and pembrolizumab compared to 0.9% with chemotherapy, with no treatment-related deaths occurring in those who achieved a complete response. These findings clearly confirm the durable efficacy of enfortumab vedotin and pembrolizumab, reinforcing its role as the standard of care for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma, and no new safety concerns have been identified. Dr. Neeraj Agarwal: Thank you for this great summary. Moving on to kidney cancer, let's talk about Abstract 439 titled, “Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate-9ER trial.” Dr. Peter Hoskin: Sure. Dr. Motzer presented the final results from the phase 3 CheckMate-9ER trial, which compared the combination of cabozantinib and nivolumab against sunitinib in previously untreated advanced renal cell carcinoma. The data after more than five years follow-up show that the combination therapy provided sustained superior efficacy compared to sunitinib. In terms of overall survival, we see an 11-month improvement in median OS, 46.5 months for the cabo-nivo versus 35.5 months for sunitinib and a 42% reduction in the risk of disease progression or death, with median progression-free survival nearly doubling – that's 16.4 months in the combination group and 8.3 months with sunitinib. Importantly, the safety profile was consistent with the known safety profiles of the individual medicines, with no new safety concerns identified. Dr. Neeraj Agarwal: Great summary, Peter. These data further support the efficacy of cabo-nivo combination therapy in advanced renal cell carcinoma, which is showing a 11-month difference in overall survival. Dr. Peter Hoskin: Neeraj, before wrapping up this podcast, would you like to tell us about Abstract 618? This is titled “Prospective COTRIMS (Cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma) trial: Final results.” Dr. Neeraj Agarwal: Sure, Peter. I would be delighted to. Dr Heidenrich from the University of Cologne in Germany presented the COTRIMS data evaluating retroperitoneal LN dissection in patients with clinical stage 2A/B seminomas. Seminomas are classified as 2A or B when the disease spreads to the retroperitoneal lymph nodes of up to 2 cm (CS IIA) or of more than 2 cm to up to 5 cm (CS 2B) in maximum diameter, respectively. They account for 10-15% of seminomas and they are usually treated with radiation and chemotherapy. However, radiation and chemo can be associated with long-term toxicities such as cardiovascular toxicities, diabetes, solid cancers, leukemia, particularly for younger patients. From this standpoint, Dr Heidenrich and colleagues evaluated unilateral, modified template, nerve-sparing retroperitoneal lymph node dissection as a less toxic alternative compared to chemo and radiation. They included 34 patients with negative AFP, beta-HCG, and clinical stage 2A/B seminomas. At a median follow-up of 43.2 months, the trial demonstrated great outcomes: a 99.3% treatment-free survival rate and 100% overall survival, with only four relapses. Antegrade ejaculation was preserved in 88% of patients, and severe complications such as grade 3 and 4 were observed in 12% of patients. Pathological analysis revealed metastatic seminoma in 85% of cases, with miR371 being true positive in 23 out of 24 cases and true negative in 100% of cases. It appears to be a valid biomarker for predicting the presence of lymph node metastases. These findings highlight retroperitoneal lymph node dissection is feasible; it has low morbidity, and excellent oncologic outcomes, avoiding overtreatment in 80% of patients and sparing unnecessary chemotherapy or radiotherapy in 10-15% of cases. Dr. Peter Hoskin: Great summary and important data on retroperitoneal lymphadenectomy in metastatic seminoma. These findings will help shape clinical practice. Any final remarks before we conclude today's podcast? Dr. Neeraj Agarwal: Before wrapping up this podcast, I would like to say that we have reviewed several abstracts addressing prostate, bladder, kidney cancers, and seminoma, which are impacting our medical practices now and in the near future. Peter, thank you for sharing your insights with us today. These updates are undoubtedly exciting for the entire GU oncology community, and we greatly appreciate your valuable contribution to the discussion and your leadership of the conference. Many thanks. Dr. Peter Hoskin: Thank you, Neeraj. Thank you for the opportunity to share this information more widely. I'm aware that whilst we have nearly 6,000 delegates, there are many other tens of thousands of colleagues around the world who need to have access to this information. And it was a great privilege to chair this ASCO GU25. So, thank you once again, Neeraj, for this opportunity to share more of this information that we discussed over those few days. Dr. Neeraj Agarwal: Thank you, Peter. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  Find out more about today's speakers:   Dr. Neeraj Agarwal    @neerajaiims    Dr. Peter Hoskin Follow ASCO on social media:      @ASCO on Twitter      ASCO on Bluesky  ASCO on Facebook      ASCO on LinkedIn      Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Peter Hoskin: Research Funding (Institution): Varian Medical Systems, Astellas Pharma, Bayer, Roche, Pfizer, Elekta, Bristol Myers  

En la edición AM, hablamos con Kevin Cowan, académico de la Escuela de Negocios UAI y ex Vicepresidente de la CMF, y con David Fischer, abogado tributario y socio de Binatax. También, con Felipe Posada, Director y Miembro de Comunidad Traders.

Most small business owners excel in their chosen fields, but marketing often feels like uncharted territory. You know you need a website and an email list, but what should your website look like? What should you be sending to your email list? And how do you know if any of it is even working?David Fischer, Founder and CEO of Solutions for Growth and Constant Contact Community Coach, understands these challenges. For 14 years, he and his team have helped small businesses nationwide elevate their marketing efforts and get real results.David joined Dave Charest on the Be a Marketer podcast to share his insights on how to level up your email marketing using the power of segmentation. Simply put, segmentation means dividing your email list into smaller groups based on specific criteria, like demographics, purchase history, or even engagement levels. This allows you to send more personalized and relevant emails that resonate with each subscriber.“The more targeted and more specific the message is to those people, the more it will resonate with them and the better results you're going to get," David explains.Tune in to learn tactical tips for segmenting your email list, understanding the difference between lists and segments, and sending the right message to the right people at the right time.Additional Resources:Email List SegmentationSegment Your ListsEmail List Segmentation Best Practices

On the surface, the election of 1872 might seem insignificant in US history; Ulysses Grant easily won reelection to the White House and his Republican Party maintained their dominance in both houses of Congress. In the south, however, the violence that followed the election at the state and local level was an ominous sign that the era of Reconstruction might soon be over. And, according to Dana Bash and her co-author David Fischer, nowhere saw more violence than Louisiana. In this episode, Dana joins Ben & Bob to discuss her new book America's Deadliest Election: The Cautionary Tale of the Most Violent Election in American History, and how the violence that followed the 1872 election in Louisiana – including the slaughter of 150 unarmed black Americans in the small town of Colfax – laid the foundation for the restoration of white supremacy in the south. Dana Bash is chief political correspondent at CNN, where she also anchors Inside Politics and co-anchors State of the Union alongside Jake Tapper. This episode was edited by Gary Fletcher.

On episode #181, I spoke with David Fischer about the new movie, Sight. Here are some key questions and topics from our discussion:Who is Ming Wang?What made David want to produce a movie based on his lifeThe importance of Ming Wang's storyAnd much more... Tune in for a great conversation!Links:David on LinkedInCheck out the movie hereOur Sponsors:This is a Good Catholic Podcast.  If you're interested in purchasing a Good Catholic digital series, use code GBS for 20% off your total order.Looking for the perfect Catholic gift? Check out The Catholic Company and find it today! Use code SAINTS20OFF for 20% off your next purchase! Support the Show.

Money Monday: March 25, 2024. CRITICAL FINANCIAL NEWS! Steve has an important conversation with David Fischer from Landmarkgold about critical financial issues that are happening now and very soon. Will the stock market crash again? Our goal is to apply Biblical Truth to the big issues of the day and to spread the Good News of the Gospel to as many people as possible through the airwaves as well as digitally. This mission, like others, requires funding. So, if you feel led to help support this effort, you can make a tax-deductible donation online HERE.   Thank You!